Patents Examined by Claire Kaufman
  • Inhibitor Peptides of ERK-type MAP kinase
    Patent number: 10494410
    Abstract: The invention concerns peptides useful as MAP kinase/ERK pathway-specific inhibitors relative to a given substrate in a given subcellular compartment.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: December 3, 2019
    Assignees: UNIVERSITE PIERRE ET MARIE CURIE, Centre National de la Recherche Scientifique—CNRS—
    Inventors: Jocelyne Caboche, Peter Vanhoutte
  • Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
    Patent number: 10428132
    Abstract: The present invention discloses a tumor necrosis factor-related apoptosis-inducing ligand variant, which is a fusion protein of a tumor necrosis factor-related apoptosis-inducing ligand and an F3 peptide. The F3 peptide is fused to the N-terminus or C-terminus of the tumor necrosis factor-related apoptosis-inducing ligand by a linker. The present invention also discloses a nucleotide sequence, as well as a recombinant vector and a recombinant bacterium comprising same, and also discloses a preparation method and use of the foregoing variant.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: October 1, 2019
    Assignee: WEST CHINA HOSPITAL, SICHUAN UNIVERSITY
    Inventors: XiaoFeng Lu, Hao Yang, Lin Wan, JingQiu Cheng
  • Modified natural killer cells that express IL15 and uses thereof
    Patent number: 10428305
    Abstract: The present invention provides, in certain aspects, a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15), and methods for producing such cells. The invention further provides methods of using a natural killer (NK) cell that expresses all or a functional portion of interleukin-15 (IL-15) to treat cancer in a subject or to enhance expansion and/or survival of NK cells.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: October 1, 2019
    Assignees: National University of Singapore, St. Jude Children's Research Hospital, Inc.
    Inventors: Dario Campana, David Shook, Masaru Imamura
  • Anti-DR6 antibodies and methods of immune regulation
    Patent number: 10370450
    Abstract: The problems: It is an object of the present invention to provide an immune regulating agent capable of modulating a receptor function concerning immune regulation of DR6, and a method for screening thereof. The object aims to provide: The present invention relates to an immune regulating agent containing a physiologically active substance having an ability to bind specifically to DR6 and an ability to regulate signal transduction induced by specific binding between DR6 and Sdc1, as an active component. The immune regulating agent of the present invention can be used for treating or preventing diseases caused by excessive or abnormal immune response in mammals or diseases for which enhancement of immune function is desired in mammals, as an immune regulating agent based on a hitherto unknown mechanism, capable of regulating signal transduction induced by specific binding between DR6 and Sdc1.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: August 6, 2019
    Assignee: National University Corporation Hokkaido University
    Inventors: Daisuke Fujikura, Toshimitsu Uede
  • Membrane-anchoring and apoptosis-inducing fusion protein comprising a fragment of TRAIL and CD40L and encoding polynucleotides
    Patent number: 10370422
    Abstract: Provided are compositions comprising fusion proteins, polynucleotides and/or expression vectors with therapeutic utility for suppressing and/or treating cancer, as well as medical uses of these agents, and methods of treatment in which they are used. A fusion protein of the invention comprises an amino acid sequence that provides the apoptosis-inducing activity of TRAIL, and a membrane-anchoring amino acid sequence. The amino acid sequence that provides the apoptosis-inducing activity of TRAIL comprises the extracellular domain of TRAIL, or a fragment or variant thereof. A fusion protein comprising an amino acid sequence from TRAIL that is able to induce apoptosis, and a second sequence that anchors the first sequence to the cell membrane, is markedly more effective at reducing viability of TRAIL receptor positive cells than the naturally occurring (“wild type”) TRAIL protein itself.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: August 6, 2019
    Assignee: The University of Liverpool
    Inventors: Daniel Palmer, Taha Elmitwalli
  • Treatment of cancer with dual targeting of CD47 and EGFR
    Patent number: 10344094
    Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 9, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
  • Multivalent and multispecific DR5-binding fusion proteins
    Patent number: 10308720
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: June 4, 2019
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
    Patent number: 10309966
    Abstract: The present invention relates to in vitro methods of assessing the susceptibility or responsiveness of a subject to the treatment with an epidermal growth factor receptor (EGFR) inhibitor/antagonist, wherein the subject has been diagnosed or suspected of suffering from inflammation-associated cancer. These methods comprise determining the level of expression of EGFR in myeloid cells in a sample from the subject, wherein an expression of EGFR in the myeloid cells is indicative of the subject being susceptible to the treatment with an EGFR inhibitor/antagonist.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: June 4, 2019
    Assignee: Medizinische Universität Wien
    Inventor: Maria Sibilia
  • Variants of DR3 and use thereof
    Patent number: 10308703
    Abstract: Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: June 4, 2019
    Assignee: THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY I
    Inventors: Amir Aharoni, Itay Levin
  • Methods for achieving therapeutically effective doses of anti-CD47 agents
    Patent number: 10301387
    Abstract: Methods are provided for treating a subject with a therapeutic dose of anti-CD47 agent by administering a primer agent prior to administering a therapeutically effective dose of an anti-CD47 agent to the subject.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: May 28, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Stephen Willingham, Maureen Howard, Jie Liu, Ravindra Majeti, Susan Sweeney Prohaska, Anne Kathrin Volkmer, Jens-Peter Volkmer, Irving L. Weissman
  • TAT-CrmA anti-apoptotic fusion proteins
    Patent number: 10301375
    Abstract: The present invention relates to a fusion protein comprising a protein transduction domain capable of introducing the fusion protein into a mammalian cell and an anti-apoptotic protein comprising the amino acid of the sequence of SEQ ID NO:1 or an anti-apoptotically active variant or fragment thereof. The invention also relates to a pharmaceutical composition comprising such a fusion protein, in particular for blocking apoptosis in a patient in need thereof. The invention also provides a polynucleotide encoding such a fusion protein, an expression vector comprising the polynucleotide and a host cell comprising the expression vector. In a further aspect, the invention relates to the use of any of theses materials for the preparation of a medicament for blocking apoptosis in a patient in need thereof.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 28, 2019
    Assignee: Unipeak Consulting SDN BHD
    Inventors: Ulrich Kunzendorf, Stefan Krautwald
  • Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules
    Patent number: 10279037
    Abstract: This document provides methods and materials involved in modulating a cell's ability to be resistant to apoptosis. For example, methods and materials for exposing cells to KLK6 polypeptides, or increased KLK6 polypeptide activity, to promote resistance to apoptosis are provided. In addition, methods and materials for reducing the ability of KLK6 polypeptides to promote resistance to apoptosis are provided.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: May 7, 2019
    Assignee: Mayo Foundation for Medical Education and Research
    Inventor: Isobel A. Scarisbrick
  • Apolipoprotein O and fragments thereof for inducing apoptosis in a cancerous cell
    Patent number: 10272135
    Abstract: The invention relates to a compound for use for inducing apoptosis in a cancerous cell, wherein said compound is selected from the group consisting of ApoO, a variant or a fragment thereof, their mixtures, and a vector encoding for said ApoO, variant or fragment thereof. The invention further relates to a compound for use for treating a pathophysiological situation, wherein said compound is an inhibitor of the ApoO activity or of the ApoO gene expression.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: April 30, 2019
    Inventors: Philippe Rouet, Fatima Smih
  • Antibody binding sites specific for EGFRvIII
    Patent number: 10273309
    Abstract: This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: April 30, 2019
    Assignee: AFFEMED GMBH
    Inventors: Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Vera Molkenthin, Melvyn Little, Eugene Zhukovsky
  • Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
    Patent number: 10266599
    Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: April 23, 2019
    Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Urs Beat Hagemann, Remko Griep, Herald Reiersen, Sergej Michailovi{hacek over (c)} Kiprijanov
  • Fusion proteins binding to VEGF and angiopoietin
    Patent number: 10259860
    Abstract: The present application discloses an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and Angiopoietin polypeptide, which includes a nucleotide sequence encoding a Tie2 component and a VEGFR component.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: April 16, 2019
    Assignee: APROGEN INC.
    Inventors: Hak-Zoo Kim, Young Jun Koh, Ho-Min Kim, Keehoon Jung, Choonjoo Jeon, Gou Young Koh
  • Modified T lymphocytes comprising an inducible caspase and methods of apoptosis
    Patent number: 10238690
    Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 26, 2019
    Assignee: CELGENE CORPORATION
    Inventors: Stewart Abbot, Tianjian Li, Bitao Liang
  • TNF alpha antibody or fragment thereof and methods of use
    Patent number: 10233238
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: March 19, 2019
    Assignee: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • Angiopoietin-related protein 4 (cAngptl4) as a diagnostic biomarker for acute lung damage
    Patent number: 10160803
    Abstract: The invention relates to the C-terminal fragment of angiopoietin-related protein 4 [cAngptl4] as a diagnostic marker for viral and bacterial pneumonia; anti-angiopoietin-related protein 4 therapeutic antibodies, and the use of anti-angiopoietin-related protein 4 antibodies in the treatment of viral and bacterial pneumonia.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: December 25, 2018
    Assignees: National University of Singapore, Nanyang Technological University
    Inventors: Vincent Tak Kwong Chow, Nguan Soon Tan, Liang Li, Ming Jie Tan, Han Chung Kelvin Chong
  • Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
    Patent number: 10138289
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment, homologous or orthologues protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: November 27, 2018
    Assignee: Delphi Genetics S.A.
    Inventors: Jean-Christophe Renauld, Muriel Lemaire, Laurie Dumoutier, Yannick Nizet, Alain Vanderplasschen, Laurent Gillet, Sophie Scohy, Cédric Szpirer